Compare Charles River Laboratories Intl. Inc (CRL) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Health Care Select Sector SPDR Fund — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Health Care Select Sector SPDR Fund trades at $170.81 (market cap $43.48B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 3.1× Charles River Laboratories Intl. Inc's market cap, and Health Care Select Sector SPDR Fund is more actively traded (11,121,431 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| CRL | XLV | |
|---|---|---|
Market Cap | $14.23B | $43.48B |
Volume | 1,176,885 | 11,121,431 |
Sector | Health | — |
52-Week High | $310.77 | $175.68 |
52-Week Low | $149.93 | $141.95 |
Typical Hold Time | 33 Days | 100 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
XLV trades at $168.16, down 0.39% with a bearish technical signal from moving averages. The healthcare ETF maintains strong cost advantages with a 0.08% expense ratio compared to peers. Recent news highlights XLV's defensive positioning during market volatility and its historical outperformance during Fed rate hikes. Technical indicators show RSI levels in neutral territory while ADX signals selling pressure.
XLV offers diversified healthcare exposure with competitive expense ratios, positioning it well for defensive investing. Key risks include political uncertainty around healthcare policy and concentrated exposure to domestic S&P 500 stocks. The ETF's low-cost structure and sector diversification provide stability amid market volatility, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
